TEVA PHARMACEUTICALS, INC
Last updated Jun 18, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
66%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Not specified
Highest priority development: S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for TEVA PHARMACEUTICALS, INC; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 66%
Active Signals
1
Investigate Priority
0
Opportunity Score
12
Buyer Quality
3 · Low Priority
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 18, 2026Score 12TEVA Pharmaceuticals submits ANDA219413 for FDA review
Not specified
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and AnswersModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee ActModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived PharmaceuticalsModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA-TRACK: Prescription Drug User Fee Act Review Goals SummaryModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to TEVA PHARMACEUTICALS, INC right now?
- Which regulatory precedents should TEVA PHARMACEUTICALS, INC monitor in Not specified?
- Which pipeline programs should TEVA PHARMACEUTICALS, INC prioritize for competitive review?
- What signals require immediate investigation for TEVA PHARMACEUTICALS, INC?
- Summarize the strategic implications of recent developments for TEVA PHARMACEUTICALS, INC.
- Where is the greatest uncertainty in TEVA PHARMACEUTICALS, INC's competitive positioning?